Cash from Financing (Quarterly) Chart

View Cash from Financing (Quarterly) for DGWPF.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Cash from Financing (Quarterly) Chart
Start Trial

Historical Cash from Financing (Quarterly) Data

View and export this data back to 2004. Start Trial.
Date Value
June 30, 2026 -50.42M
March 31, 2026 -68.98M
December 31, 2025 -36.62M
September 30, 2025 -54.60M
June 30, 2025 6.192M
March 31, 2025 -12.74M
December 31, 2024 -36.16M
September 30, 2024 -66.27M
June 30, 2024 12.71M
March 31, 2024 -81.69M
December 31, 2023 -32.84M
September 30, 2023 -49.55M
June 30, 2023 -13.04M
March 31, 2023 -71.34M
December 31, 2022 15.27M
September 30, 2022 -7.454M
June 30, 2022 -29.18M
March 31, 2022 -10.69M
December 31, 2021 -9.944M
September 30, 2021 -88.29M
June 30, 2021 -16.14M
March 31, 2021 -286.24M
December 31, 2020 115.26M
September 30, 2020 -18.06M
June 30, 2020 41.89M
Date Value
March 31, 2020 -5.523M
December 31, 2019 -32.94M
September 30, 2019 -27.26M
June 30, 2019 0.918M
March 31, 2019 -39.07M
December 31, 2018 19.66M
September 30, 2018 -14.24M
June 30, 2018 -11.07M
March 31, 2018 -2.287M
December 31, 2017 1.322M
September 30, 2017 -1.259M
June 30, 2017 -11.63M
March 31, 2017 -33.41M
December 31, 2016 -45.06M
September 30, 2016 -20.42M
June 30, 2016 -26.08M
March 31, 2016 14.67M
December 31, 2015 24.44M
September 30, 2015 -30.49M
June 30, 2015 32.30M
March 31, 2015 -28.56M
December 31, 2014 43.05M
September 30, 2014 -28.53M
June 30, 2014 -12.64M
March 31, 2014 -41.17M

Cash From Financing Definition

Represents the net cash flow resulting from the company's financing activities. Financing activities represent movement in the company's debt and share capital and other activities.

Read full definition.

Cash from Financing (Quarterly) Range, Past 5 Years

View Cash from Financing (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Cash from Financing (Quarterly) Benchmarks

View Cash from Financing (Quarterly) Benchmarks
Start Trial
Ottobock SE & Co. KGaA 117.76M
Abbott Laboratories -3.518B
AngioDynamics, Inc. -0.108M
Alphatec Holdings, Inc. -19.53M
AtriCure, Inc. 3.262M